Skip to main content

Benefit/Risk Ratio of Aspirin

Buy Article:

$39.50 plus tax (Refund Policy)

Abstract:

Aspirin is an efficacious drug with increasing medical use. In order to minimize its risk and increase its safety, it should not be used in those high risk individuals with severe asthma, those with steroid-dependent asthma, and those with nasal polyps. I do not believe that it should be indescriminately withheld from all asthmatics, especially those low risk groups with mild extrinsic asthma and no nasal polyps.

Aspirin challenge studies should be done on a double blind-placebo basis with criteria that not only includes pulmonary function tests, but also objective physical signs and symptoms.

Studies of identical twins reveal that when both twins have asthma, only one of the twins may have nasal polyps and aspirin intolerance.

The term aspirin intolerance is vague and should be replaced, perhaps by the term anaphylactoid reactions to aspirin.

Document Type: Research Article

DOI: https://doi.org/10.2500/108854181779090921

Publication date: 1981-03-01

More about this publication?
  • Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.

    The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.

    Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.

    Articles marked "F" offer free full text for personal noncommercial use only.

    The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Information for Advertisers
  • Reprint Requests
  • www.AJRA.com
  • www.AllergyandRhinology.com
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more